Table 1 Characteristics of the studies included in this review
Author | Year | Country | Design | Follow-up (months) | Intervention | No. of eyes | Age(years) | ∆Kmax (D) | ∆CDVA (logMAR) | ∆Corneal thickness (μm) |
|---|---|---|---|---|---|---|---|---|---|---|
Soeters, N | 2015 | Netherlands | Randomized Controlled Trial | 12 | Standard CXL | 24 | 24(18–44) | -1.5 ± 2.0 | -0.07 ± 0.21 | −4 ± 8 |
Transepethelial CXL | 33 | 24(18–48) | 0.3 ± 1.8 | −0.14 ± 0.21 | 0 ± 12 | |||||
Bikbova, G | 2016 | Russia | Randomized Controlled Trial | 24 | Standard CXL | 73 | 30(18–42) | −1.89 ± 3.023 | −0.02 ± 0.2793 | −13 ± 37.2252 |
Transepethelial CXL | 76 | 28(18–44) | −0.74 ± 3.0494 | −0.07 ± 0.4525 | −6.72 ± 38.61118 | |||||
Lombardo, M | 2017 | Italy | Randomized Controlled Trial | 12 | Standard CXL | 12 | 29.4 ± 5.6 | −0.82 ± 1.20 | −0.03 ± 0.06 | −1 ± 494.60 |
Transepethelial CXL | 22 | 31.0 ± 6.6 | −0.52 ± 1.30 | −0.10 ± 0.12 | 9 ± 489.81 |